H1 2023 Financial Highlights

Oncology Key ongoing clinical-trial highlights TRIAL POPULATION PATIENTS DESIGN PRIMARY ENDPOINT(S) STATUS Tazverik ARIA Tazverik in various Phase Ib/II R/R hematologic malignancies 156 combinations: multi-cohort Phase lb: dosing, safety Phase II: ORR Recruiting1 NCT05205252 IPN 60210 Phase I/lb NCT05121103 R/R multiple myeloma & R/R DLBCL 96 IPN60210 Treatment-emergent adverse events, dosing & ORR Tazverik CELLO-1 Phase Ib/II NCT04179864 IPSEN Innovation for patient care mCRPC: patients who have not received chemotherapy Enzalutamide + Tazverik Phase lb: dosing, safety or 104 abiraterone/prednisone + Tazverik Phase II: rPFS Tazverik + enzalutamide 1. Recruitment status as per ct.gov, June 2023. R/R: relapsed/refractory; ORR: objective response rate; DLBCL: diffuse large B-cell lymphoma; mCRPC: metastatic castration-resistant prostate cancer; rPFS: radiographic progression-free survival. Recruiting1 Active, not recruiting1 27

View entire presentation